The main purpose of this legislation is to ensure that access to genetically targeted technologies, particularly advanced drug products, is protected and encouraged. It aims to foster innovation in the field of medicine by extending the period during which certain drugs can be exclusively marketed, thereby incentivizing the development of new treatments that utilize genetic technologies. Key provisions of this legislation include an amendment to the definition of what constitutes a qualifying single source drug under the Social Security Act.